115.40% Gross profit margin 61.51% 59.98% 1.53% Net profit margin 45.50% 36.59% 8.91% บริษัท ดโีอด ีไบโอเทค จ ำกดั (มหำชน) 111 หมู่ที่ 2 ต ำบลท่ำจีน อ ำเภอเมืองสมุทรสำคร จังหวดัสมุทรสำคร 74000 111 Moo 2

shortfall as above mentioned. Net Profit Statements of Financial Position and THB million Y18 Y17 %Chg As Reported (% to Sales) Total Admin Exp. 256(12.4%) 176(12.8%) 45.3% TKS 169(13.4%) 174(12.6%) (3.1

Board 1/2019 on February 25,2019 has been approved the financial statements for year ended 31 December 2018 The Company net profit of 170.42 million baht which decrease 161.95 million baht or (48.72)% by

, 2018 showed total revenue of 171.32 million Baht. The cost of sales amounted to 126.04 million Baht, while selling and administrative expenses and financial costs were 28.07 million Baht in total. Net

Manager of the Stock Exchange of Thailand For the Q3/2019 period ended of September 30, 2019 (9 months) operating result of the company net loss Baht 0.22 Million comparison with the previous Q3/2018’s net

Company Limited would like to clarify the operating results of the year ended December 31, 2019that has net Profit of Baht 71.52 million, decreased from the same period of previous year that has net profit

Company Limited and Subsidiaries hereafter refer as (The Company) would like to clarify the Company’s operating results for the year ended December 31, 2019. The Company had the net profit of 50.94 million

, 2019, in order to disclose as the information to the investor and public. For the Year 2019 performance ended 31 December 2019, the company has a net profit of 70.18 million baht, compared to the same

to 130.80 million Baht, while cost of distributions and administrative expenses and financial costs were 34.22 million Baht in total. Net income for the period of the company was 9.71 million Baht. The

Baht 262.16 million respectively, which increased by Baht 22.51 Million or equivalent to 8.59% from 2016 The net profit (loss) of the company share holders’ part is Baht 47.88 Million of the first